Cannabis use disorder (CUD) is a psychiatric condition defined by continued cannabis use despite clinically significant impairment or distress. It is diagnosed using DSM-5 or ICD criteria and can include tolerance, withdrawal, and functional impairment.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07523633 |
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder |
RECRUITING | PHASE2 |
| NCT00673647 |
CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS |
UNKNOWN | PHASE3 |
| NCT00613405 |
Stress and Marijuana Cue-elicited Craving and Reactivity |
COMPLETED | NA |
